Neurocrine Bioscienc (NBIX)

$124.52 -0.48 (-0.38%)
Market Cap 12.17B
Revenue (ttm) 2.36B
Net Income (ttm) 341.30M
EPS (ttm) N/A
PE Ratio 42.22
Forward PE 32.88
Profit Margin 14.49%
Debt to Equity Ratio 0.00
Volume 833,400
Avg Vol 1,611,448
Day's Range N/A - N/A
Shares Out 98.97M
Stochastic %K 87%
Beta 0.26
Analysts Strong Sell
Price Target $161.08

Latest News on NBIX

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

Jun 2, 2025, 7:30 PM EDT - 2 days ago

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

Jun 2, 2025, 8:30 AM EDT - 2 days ago

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

May 28, 2025, 7:43 PM EDT - 7 days ago

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

May 28, 2025, 4:05 PM EDT - 7 days ago

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

May 16, 2025, 8:30 AM EDT - 19 days ago

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

May 16, 2025, 8:25 AM EDT - 19 days ago

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

May 15, 2025, 4:05 PM EDT - 20 days ago

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia

May 14, 2025, 4:05 PM EDT - 21 days ago

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

May 8, 2025, 8:30 AM EDT - 27 days ago

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

May 6, 2025, 4:01 PM EDT - 4 weeks ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

May 6, 2025, 1:24 PM EDT - 4 weeks ago

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

May 6, 2025, 8:30 AM EDT - 4 weeks ago

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript

May 5, 2025, 8:33 PM EDT - 4 weeks ago

Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript

Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

May 5, 2025, 4:01 PM EDT - 4 weeks ago

Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

May 5, 2025, 8:30 AM EDT - 4 weeks ago

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

Apr 30, 2025, 7:35 PM EDT - 5 weeks ago

Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Apr 30, 2025, 8:00 AM EDT - 5 weeks ago

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Apr 24, 2025, 4:05 PM EDT - 5 weeks ago

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Apr 22, 2025, 6:05 PM EDT - 6 weeks ago

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity

Apr 16, 2025, 5:51 PM EDT - 7 weeks ago

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

Apr 4, 2025, 8:00 AM EDT - 2 months ago

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Mar 31, 2025, 8:30 AM EDT - 2 months ago

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Mar 20, 2025, 8:30 AM EDT - 2 months ago

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Mar 17, 2025, 8:30 AM EDT - 2 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 4:01 PM EDT - 3 months ago

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Mar 5, 2025, 8:30 AM EST - 3 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Feb 27, 2025, 4:05 PM EST - 3 months ago

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Feb 25, 2025, 4:01 PM EST - 3 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Feb 21, 2025, 8:00 AM EST - 3 months ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Feb 7, 2025, 1:05 PM EST - 4 months ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 10:52 PM EST - 4 months ago

Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

Feb 6, 2025, 4:01 PM EST - 4 months ago

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval

Feb 4, 2025, 7:52 AM EST - 4 months ago

Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

Jan 30, 2025, 4:01 PM EST - 4 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Jan 28, 2025, 8:30 AM EST - 4 months ago

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Jan 27, 2025, 4:05 PM EST - 4 months ago

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Jan 23, 2025, 4:05 PM EST - 4 months ago

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Jan 21, 2025, 4:05 PM EST - 4 months ago

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Jan 13, 2025, 7:04 PM EST - 5 months ago

Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Jan 8, 2025, 8:30 AM EST - 5 months ago

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:01 PM EST - 5 months ago

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 20, 2024, 8:00 AM EST - 5 months ago

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Dec 18, 2024, 10:11 AM EST - 6 months ago

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 13, 2024, 6:55 PM EST - 6 months ago

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

US FDA approves Neurocrine Biosciences' genetic disorder drug

Dec 13, 2024, 5:50 PM EST - 6 months ago

US FDA approves Neurocrine Biosciences' genetic disorder drug

Neurocrine Biosciences to Participate at Investor Conferences in December

Nov 26, 2024, 4:01 PM EST - 6 months ago

Neurocrine Biosciences to Participate at Investor Conferences in December

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

Nov 8, 2024, 11:02 AM EST - 7 months ago

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Nov 7, 2024, 8:30 AM EST - 7 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences to Participate at Investor Conferences in November

Nov 5, 2024, 4:01 PM EST - 7 months ago

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Nov 4, 2024, 8:30 AM EST - 7 months ago

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules